Navigation Links
ESTEVE Communicates its R&D Through a New Interactive Platform
Date:7/12/2012

BARCELONA, July 12, 2012 /PRNewswire/ --

This site is part of the  http://www.esteve.com  corporate web portal

  • ESTEVE's new website provides consise and updated information on its projects under development. Among these is the S1RA (Sigma-1 Receptor Antagonist), a new chemical entity, presently in Clinical Phase II, for treating several types of pain
  • In addition to defining the Company's main lines of research, this new website also discloses the Company's different and innovative models of collaboration

ESTEVE announces the launch of a new website (http://www.esteve.es/EsteveFront/IDI.do?lng=en) with the purpose of communicating the Company's R&D and the innovative models of collaboration currently implemented. Newly formatted and fully integrated in the http://www.esteve.com web portal, this site reinforces the commitment of ESTEVE to R&D with emphasis on a solid strategy to provide new therapeutic solutions for unmet medical needs in highly prevalent diseases of high social impact.

With its primary focus in analgesia, ESTEVE is developing innovative therapies for pain. Two projects are presently undergoing clinical development for the treatment of neuropathic pain and moderate to severe acute and chronic pain.

One of these projects involves S1RA, a highly selective Sigma-1 Receptor Antagonist that offers a new approach and a new mechanism of action in a field (neuropathic pain) strongly in need of novel, more effective and safer therapies.

The new website also describes the innovative partnering strategy in R&D as well as ESTEVE's network of excellence built through unique collaborative models. This network includes different types of alliances, from public-private partnerships -such as the HIVACAT program to develop an effective vaccine against HIV and the Sanfilippo project to develop a treatment for a rare childhood disease- to R&D consortiums such as Neogenius for pain research.

One of the key features of this site is its attractively designed interface for portfolio presentation, which includes the various ongoing R&D programs, i.e. in-house projects in analgesia, projects in collaboration with other centers or companies, and in-licensed projects.

With language and information customized for each audience, this new website provides specific information for scientists, healthcare providers, industry partners, patients and other stakeholders.

About ESTEVE

ESTEVE is a leading chemical-pharmaceutical group in Spain and has a strong international presence. Ever since its foundation in 1929, ESTEVE has been firmly committed to excellence and has been using its best efforts to promote health and improve people's quality of life.



'/>"/>
SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. BIRD - Israel-US Binational Industrial R&D Foundation to Invest $7.15 Million in Eight New Projects
2. picoSpin-45 Miniature NMR Spectrometer Wins R&D 100 Award
3. ORNL wins 9 R&D 100s, bringing total to 173
4. New life sciences R&D model based on real-time learning and data-sharing needed to sustain innovation
5. Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Mandy Moore Campaigns for Clean Water, GreenBeanBuddy Encourages Mothers to Help Through the Use of Green Cleaning Products
8. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
9. Nanodiamonds cut through dirt to bring back bling to low-temperature laundry
10. Soundbites Breaks Through at 47th AES Conference
11. PharmaDirections Succeeds Through its Client’s Successes: Cortendo Receives Positive Orphan Drug Opinion from EMA for NormoCort for Cushing’s Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
(Date:6/22/2016)...  According to Kalorama Information, the dominant trends ... include significant efforts in automation as well as ... affordable sequencers, say the healthcare market research firm, ... sample prep materials.  The healthcare market research company,s ... Next Generation Sequencing (NGS) , highlights major trends ...
(Date:6/22/2016)... ... June 22, 2016 , ... The Immigrant ... achievements and contributions to North Texas and the nation, recently held its annual ... community to the civic and economic vitality of North Texas. Proceeds from the ...
Breaking Biology Technology:
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
Breaking Biology News(10 mins):